Why should you choose VeriRef® & VeriRef Gold®?

VeriRef® has the technical accreditation UNE-EN-ISO 15189. Includes satisfactory results of external quality control.

All the equipment: platform, software and consumables are **CE-IVD marked.**

Carried out in Spain, at Reference Laboratory Genetics' facilities.

Shortest turnaround times: 3-5 working days.

Lowest failure rate: <0.1%.

Test supported by the largest number of publications (Verifi® and VeriSeq® by ILLUMINA).

Enables the study of possible reasons for pregnancy loss and a more accurate pregnancy management.

VeriRef Gold® detects aneuploidies and CNVs in all chromomes, detecting rare chromosomal aneuploidies.

Suitable for any BMI, ethnic group, in vitro fertilisation and egg donation.

Quantifies in a detailed and very sensitive way the **fetal fraction** of each sample.

For high-risk results, we notify the prescriber health care professional immediately and offer **FREE CONFIRMATION with QF-PCR or CGH Array** from a sample of amniotic fluid.

Currently **operative integration of results in any SIL** of the Laboratory.

Technology: MPS-Massive Parallel Sequencing. Allows the extension of the study to new chromosomes.

As early as the **10th week of gestation.**

REFERENCE LABORATORY GENETICS

C/ Pablo Iglesias, 57
08908 Hospitalet de Llobregat
Barcelona · (+34) 932 593 700
www.reflabgenetics.com

verief.ENTO221G

VeriRef®

Detection of aneuploidies in chromosomes 13, 18, 21, X and Y in maternal blood

VeriRef Gold®

Detection of aneuploidies and CNVs in all chromosomes in maternal blood



VeriRef® & VeriRef Gold®

Genome-wide non invasive prenatal testing

VeriRef® is a highly accurate NIPT that analyses the risk of aneuploidies in chromosomes 13, 18, 21, X and Y in the fetus, by studying the fetal DNA in maternal blood.

For those cases where more information is required, we have developed VeriRef Gold®, which detects aneuploidies and CNVs in all chromosomes.

In addition, by expanding the study of chromosomal alterations to all chromosomes, VeriRef Gold® is a simple alternative to the karyotyping of products of conception for the study of possible reasons for pregnancy loss.

SAFE | SIMPLE | ACCURATE

POWERED BY illumina®

Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.

VeriRef Gold®

Detects rare chromosomal alterations

Aneuplodies and CNVs (deletions and duplications) in all chromosomes

16% of the chromosomal alterations are not in chromosomes 21, 18, 13, X and Y[1].



VeriRef Gold® detects less common chromosomal alterations not covered by other NIPT technologies[2].



Dr. Manuel Martínez
Scientific Director

Dr. Cristina Camprubí
Head of Genetic Diagnostics and Counselling

Pre- and post-study genetic counselling

We offer pre- and post-study genetic counselling, through personalised assistance with Dr. Manuel Martinez and Dr. Cristina Camprubi, specialist in Reproductive Genetics.

The highest accuracy at your finger tips

VeriRef® and VeriRef Gold® are the most sensitive tests on the market, with the lowest rate of not obtaining results (< 0,1%) and the lowest rate of false positives (< 0,1%)[3].

Chromosome	Sensibility (%)	Specificity (%)
Down Syndrome (21)	>99,9	99,9
Edwards Syndrome (18)	>99,9	99,9
Patau Syndrome (13)	>99,9	99,9
Monosomy X	95,0	99,9
XX	>99,9	99,8
XY	>99,9	>99,9
Rest of chromosomes	96,4	99,8

Deletions and duplications	Sensibility (%)	Specificity (%)
CNVs	74,1	99,8

All information about the limitations of VeriRef® and VeriRef Gold® can be found at www.reflabgenetics.com

When are VeriRef® and VeriRef Gold® indicated?

- Advanced maternal age
- High risk result in biochemical screening
- Suggestive ecographic traces of chromosomal alteration
- Previous history of pregnancy with chromosomal alteration
- Couples who wish to rule out chromosomal alterations
- As a first-level approach for assessing early pregnancy loss

Test code: 16200, 16203

5-10 mL maternal blood in a Streck tube

It is mandatory to send the informed consent with the sample

1. Scott et al. Rare autosomal trisomies: Important and not so rare. Prenat Diagn 2018;38:765-71

2. Pertile M, Halks-Miller M, Flowers N, et al. Rare autosomal trisomies, revealed by plasma DNA sequencing, suggest increased risk of feto-placental disease. Sci Transl Med. 2017;19(405)

3. VeriSeq NIPT Solution v2 Package Insert